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Synapse loss is an early manifestation of pathology in Alzheimer’s disease (AD) and is currently the best correlate to cognitive
decline. Microglial cells are involved in synapse pruning during development via the complement pathway. Moreover, recent
evidence points towards a key role played by glial cells in synapse loss during AD. However, further contribution of glial cells
and the role of neurons to synapse pathology in AD remain not well understood. This review is aimed at comprehensively
reporting the source and/or cellular localization in the CNS—in microglia, astrocytes, or neurons—of the triggering components
(C1q, C3) of the classical complement pathway involved in synapse pruning in development, adulthood, and AD.
1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder,
which is clinically characterized by progressive cognitive
decline finally leading to the full-blown picture of dementia
[1]. AD represents 50 to 70% of all dementia cases. Yet, it
has no cure. Synaptic loss and dendritic loss have been
observed in the hippocampus and neocortex of AD patients
[2]. The decrease in cortical synaptic density is mirrored by
changes in the presynaptic marker synaptophysin and corre-
lates with cognitive decline in AD patients [3]. Therefore,
understanding the underlying mechanisms responsible for
synapse loss during AD is of critical importance in order to
identify new therapeutic targets.
The complement system is part of the innate immune
system in multicellular organisms, and it is activated by three
biochemical pathways (explained in more detail in Section 2).
The classical complement pathway is activated when ligands
bind to C1q triggering C1 complex activation. C3, a central
protein of the complement cascade, acts as downstream of
C1q in the classical complement cascade and also activates
the alternative pathway when ligands bind directly to it.
Recent publications point towards a role played by
microglia and astrocytes in early synapse pruning during
development, presumably via the classical complement
pathway [4]. They also showed that expression of C1q
protein by retinal neurons modulated by astrocytes was a
crucial event for synaptic pruning [5].
In AD, complement components have been associated
with amyloid-β (Aβ) plaques [6, 7]. It has also been reported
that oligomeric/fibrillar Aβ and hyperphosphorylated tau
(pTau) activate the complement pathway by binding to C1q
[8–13]. C1q is upregulated and associated to synapses in the
presence of oligomeric Aβ [8]. Under these circumstances,
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the classical complement pathway activates and results in
synapse loss before Aβ deposition takes place [8]. C3 has been
localized on reactive astrocytes in human AD cases [14] and
they might contribute to synapse loss by releasing comple-
ment components themselves.
The origin and contribution of complement proteins to
synapse pruning in development and AD are not well under-
stood and require further investigation. The present review is
aimed at addressing the role of microglia and astrocytes in
complement-mediated synaptic pruning associated with
development, adulthood, aging, and AD.
2. Complement-Mediated Synapse
Pruning during Development
During development, active synapses mature, while less
active ones are engulfed and removed by microglia [15–18].
Synapse removal is regulated, among other mechanisms, by
the classical complement cascade.
The complement system can be activated by three differ-
ent pathways: (1) the classical pathway commonly is initiated
by antigen-antibody binding leading to the phagocytosis
and/or pore formation in membrane, lysis, and cell death,
(2) the alternative pathway is continuously active at low
levels and not activated by pathogen or antibody binding. It
leads to opsonization and kills pathogens, and (3) the lectin
pathways are activated by mannan-binding lectin as opposed
to antibody-antigen recognition (reviewed in [19]). In this
review, we will focus on the classical pathway. This pathway
is initiated when the antigen-antibody complex binds to the
C1q protein. In addition to antigen antibody activation of
C1q, antibody-independent activation of C1q has been con-
sistently described [9, 10, 20–22]. C1q protein is the recogni-
tion subcomponent of the C1 complex, which is composed of
one molecule of C1q, two molecules of C1r, and two mole-
cules of C1s (C1qr2s2). C1q recognizing and binding to
different ligands trigger the cascade of events leading to the
cleavage of complement component C3 into the fragments
C3a and C3b. It is worth mentioning that the cleavage
of C3 can also be directly activated by the alternative path-
way. C3b is one of the primary complement opsonins and
has been shown to tag synapses targeted for elimination
[15, 19, 23]. Further C3b cleavage gives rise to iC3b, which
subsequently binds to complement receptor 3 (CR3) in
microglia, in turn driving a response that, among others,
promotes phagocytosis of cellular structures like synapses
[24, 25]. Therefore, the cellular localization of C1q and C3
and their receptors is crucial in understanding the mecha-
nism regulating synapse removal.
In vitro and in vivo studies involving the use of mRNA
expression and immunohistochemistry techniques (Table 1)
have described the localization of C1q in neurons, both in
synaptic puncta [4, 5] and axons [5] during development.
Also, astrocyte-secreted transforming growth factor-β
(TGF-β) has been demonstrated to increase C1q expression
in neurons (Figure 1(a)) [5].
The expression of C3 protein has been shown to be cru-
cial in promoting synapse phagocytosis [24]. However, the
cellular source of C3 in the CNS during development remains
elusive. Immunohistochemical analysis revealed that C3 is
present in synaptic puncta in wild-type mice, whereas C3
knock-out (KO) mice were devoid of it [4, 15]. And, as stated
above, this led to proposing that C3 cleavage products (C3b/
iC3b) could be tagging synapses for pruning [15].
During development, binding of C3 cleavage products
to CR3 promotes phagocytosis. CR3, also called CD11b/
CD18 or mac-1, is a receptor for iC3b [26] and is
uniquely expressed by microglia in the CNS [15, 27–29].
Removal of CR3 results in increased number of synapses
in CR3 KO mice [15].
Altogether, these data suggest that during the develop-
mental period of synaptic refinement, astrocyte-secreted
TGF-β increases C1q expression in neurons. This results
in the release of C3. The ligand is subsequently cleaved
to yield C3b/iC3b fragments, which in turn bind to CR3
in microglia ultimately promoting the engulfment of syn-
apses (Figure 1(a)).
3. Synapse Pruning in Adulthood and
Normal Aging
Although synapse remodeling is described to be persistent
during life, once overproduced synapses have been removed
during postnatal development, synapse elimination is down-
regulated and remains stable (Figure 1(b)). In adulthood and
under healthy conditions, there is a reduction in the expres-
sion of C1q and C3 components [24].
A number of in vitro and in vivo studies reported that
microglial cells are the main source of C1q in adulthood
and normal aging (Table 2) [30–32]. Importantly, Linnartz
and collaborators showed that sialic acid, a cellular mem-
brane component, was crucial in preventing C1q binding to
target molecules. The study demonstrated that desialylated
neuronal structures are marked by the complement and
cleared by microglia, in a process involving CR3 [31]. This
mechanism has been related to neurites [31]. Whether this
mechanism is also involved directly in synapse removal
needs to be investigated. Even though the main source of
C1q in adulthood is microglia, C1q has also been localized
at synaptic puncta in human and mouse tissue by immuno-
histochemistry [32]. Furthermore, positive immunoreactivity
of C1q has been observed in a subset of interneurons [32, 33].
In a separate study, astrocyte-derived exosomes obtained
from human subjects showed expression of C1q [34].
Both microglia [30, 31, 35] and astrocytes [35, 36] have
been reported as primary sources of C3 in primary cultures
[30, 35]. Similar to C1q, C3 has also been detected in
astrocyte-derived exosomes from human subjects [34]. As
indicated before, C3 cleaves into different products includ-
ing C3a and C3b. C3b cleavage product iC3b binds to CR3
[24, 25], whereas C3a binds to C3aR [14].
As described in Section 2, microglial cells are the only
source of CR3 in the brain [37]. Linnartz et al. [31] reported
that removal of neurites could be mediated by CR3 under
some circumstances as indicated before.
Finally, C3a binds to C3aR, a receptor present in neu-
rons, microglia, and astrocytes [37–42]. C3a is an anaphyla-
toxin linked to proinflammatory signaling and chemotaxis
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[25, 43]. In the CNS, C3a-C3aR binding has been reported
to mediate synaptic plasticity [14, 43] and microglial
phagocytosis [14].
4. AD, Synapse Pathology, and Gliosis
The neuropathology associated with AD includes synapse
loss, neuronal loss, neurofibrillary tangles (NFT), Aβ accu-
mulation, and gliosis [44]. Neuritic senile plaques and NFT
are the two main pathological hallmarks of AD. It is widely
known that neuritic plaques are surrounded by dystrophic
neurites and activated microglia and astrocytes. Dystrophic
neurites appear early in the disease and are considered to
be aberrant axon/presynaptic terminals caused by (at least
in part) alterations in cytoskeleton and axonal flux [45–48].
NFT are intraneuronal aggregates of pTau protein [49, 50],
and NFT deposition correlates with progression of the
disease [51, 52].
Aβ, the main component of plaques, is the result of the
cleavage of amyloid precursor protein (APP) and accumulates
both intra- [53–56] and extracellularly [57, 58] leading to syn-
aptic dysfunction, which is currently the best correlate of cogni-
tive decline in patients [3]. Synaptic dysfunction is reported as
an early manifestation of AD [59]. Loss of synaptophysin has
been shown to correlate well with Aβ accumulation [60, 61].
In vitro studies in primary neuronal cultures from AD mouse
model Tg2576 showed that Aβ produced by proteolytic
cleavage of mutant SwedishAPP is sufficient to induce synapse
pathology [62], demonstrating that neurons have a cell-
autonomous mechanism for synapse removal.
Aβ aggregation and accumulation associated with AD
pathogenesis trigger an inflammatory response in affected
areas of the brain. Thus, active microglia and astrocytes
are conspicuous around neuritic plaques [63, 64]. Both
microglia and astrocytes modify their morphology to adopt
a reactive morphology and undergo functional changes
(reviewed in [65–69]). Chronic inflammation states, charac-
terized by sustained reactive gliosis, have been shown to
worsen the AD pathology (reviewed in [66]). In animal
models of AD, activated microglia undergo a change in mor-
phology, from a typical ramified structure to a more amoe-
boid morphology. This has been associated with increased
proliferation [70, 71] and expression of inflammatory
markers [70, 72]. Recently, in AD brain tissue samples,
region-specific microglial deterioration associated with
decrease in amount of microglia has been described indicating
possible differential microglial responses between AD models
and patients [68, 73]. Reactive astrocytic processes penetrate
Aβ deposit, fragmenting and isolating plaques from the sur-
rounding neuropil [63]. Additionally, reactive glia derived
from neurological disorders have been characterized using
transcriptomic profiling studies [68, 73]. Disease models sug-
gest the existence of expression of specific genetic profiles for
“disease-associated microglia” (DAM) [68, 74, 75].
Recently, activated glial cells have been linked to synapse
loss in AD. Activated microglia modulate synapse loss via the
complement pathway in an AD model [8]. Other studies
have shown that apolipoprotein E (APOE) isoforms control
for C1q accumulation in the brain and modulate phagocyto-
sis by astrocytes [76]. APOE4, the major genetic risk factor
for the late onset AD, negatively affects the rate of synapse
pruning and turnover by astrocytes. C1q protein was signifi-
cantly increased in the hippocampus of APOE4 knock-in
(KI) mice when compared with APOE3 KI mice [76]. More-
over, genome-wide association studies (GWAS) and a
network-based integrative analysis have linked genes of the
immune system—like complement CR1—with increased risk
of developing AD [77, 78].
Despite of neuron-autonomous and Aβ-induced synapse
turnover, a number of studies demonstrate that glial cells are
also associated with synapse loss in AD. The complement
system might play an important role in such a process.
5. Complement and Synapse Pathology in AD
Components of the classical complement pathway have been
associated with senile plaques [79, 80], fibrillar Aβ, NFT, and
dystrophic neurites [11, 63, 64, 81–85]. Oligomeric/fibrillar
Aβ and pTau bind to C1q and activate the complement clas-
sical pathway [8–13].
Complement components have been studied as possible
biomarkers for AD. Daborg et al. [86] found increased C3
levels in AD patients compared with patients suffering from
mild cognitive impairment but not progressing to AD. They
also showed elevated cerebrospinal fluid (CSF) CR1 levels in
mild cognitive impairment that progressed to AD and AD
patients when these groups merged. Bonham et al. [87]
showed a significant interaction between APOE4 and CSF
Table 1: Cellular localization of complement components during development.
Cell type Localization Experimental model Method Ref.
C1q
Neuron Synaptic puncta, axons
In vitro: rat primary culture
In vivo: C1qaKO, Tgfbr2−/−, C1qa−/− mice
qRT-PCR, in situ
hybridization, ICC, IHC,
WB
[4, 5]
C3
Unknown Synaptic puncta In vivo: C3KO mice IHC [4, 15]
CR3
Microglia Cell surface In vivo: CR3KO mice IHC [15]
qRT-PCR: semiquantitative PCR; ICC: immunocytochemistry; IHC: immunohistochemistry; WB: Western blot.
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C3 on both CSF Aβ and CSF pTau. Their results also indi-
cated that Aβ mediates C3 effect on pTau.
Schaffer et al. [15] demonstrated the key role played by
microglia in developmental synaptic pruning. Since then,
glial cells and the complement pathway have become increas-
ingly relevant in the study of synapse loss associated with AD.
Recently, a study demonstrated the involvement of
microglia in synapse pathology at early stages of AD,
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Figure 1: Model of complement-mediated synapse elimination during development, adulthood, and Alzheimer’s disease. (a) During early
postnatal development, synaptic pruning takes place in order to eliminate excessive or weak synapses. Astrocytes induce the expression of
C1q in neurons through TGF-β, and C1q colocalizes with synapses. The complement protein C3, which also colocalizes with synaptic
puncta, is enzymatically cleaved to smaller fragments C3a and C3b. Finally, microglia engulf the synapse through the interaction of iC3b,
the cleavage product of C3b, with its CR3 receptors. (b) In the healthy brain, synaptic pruning decreases with age to basal levels and
complement protein expression is reduced. Nonetheless, microglia and astrocytes continuously survey surrounding synapses. (c) AD brain
is characterized by progressive accumulation of extracellular and intracellular Aβ, gliosis, and neuroinflammation. Some studies have
reported the role of microglia and complement pathway on synapse loss in AD models. Neuron-derived C1q and microglia-derived C1q
are recruited to synapses and interact with Aβ. This triggers the activation of complement protein C3, expressed by both astrocytes and
microglia. C3 is cleaved to smaller fragments such as C3b and iC3b that tag synapses and bind to CR3 on microglia. All these events lead
to the removal of tagged synapses by the latter.
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preceding plaque formation [8], thus supporting the exis-
tence of a mechanism described during development and
also modulating early pathological conditions during AD.
In AD brains, C1q has been associated with oligomeric/
fibrillar Aβ and pTau, and described within neurons and
activated-microglia around plaques (Table 3; Figure 1(c))
[9–13, 88]. It was not until recently that C1q was found asso-
ciated with synapse pathology in AD. C1q expression was
increased in a region-specific manner in one-month-old
J20 AD mice [8]. A significant increase in C1q and PSD-
95 colocalization was also observed in J20 mice and also
in wild-type (WT) mice when injected with Aβ oligomers.
Subsequently, at 3 months of age, a reduction of postsynap-
tic marker PSD-95 and synaptic puncta was described in
these AD mice. In vitro and in vivo experiments also asso-
ciated oligomeric Aβ and C1q with synaptic dysfunction
and in a common pathway that resulted in synapse removal
[8]. These findings supported previously reported data indi-
cating that oligomeric—but not monomeric—Aβ activates
the complement cascade in AD [10, 12, 13] and showed
that C1q is one of the key players for synapse loss in early
preplaque AD.
Both microglia and astrocytes have been shown as
sources of C1q in AD. Microglial C1qa upregulation was
reported using fluorescence in situ hybridization techniques
in the hippocampi of both J20 and Aβ oligomer-treated
WT mice [8]. Additionally, although human AD-cultured
astrocytes showed low levels of C1q [84], astrocyte-derived
exosomes from human AD showed higher expression of
C1q compared to control cases [34]. Furthermore, astrocytic
cultures from aged 5xFAD mice showed an increase of C1q
expression compared with those from control mice [89].
Such increase was also associated with Aβ plaques. Neverthe-
less, the association between C1q expression and synapse loss
observed in the 5xFAD model requires further clarification.
As described for C1q, C3 has also been associated with
synaptic puncta in AD mice [8]. A significant increase of
C3 and PSD-95 colocalization was observed in the APP/
PS1-AD model. Deletion of C3 in APP/PS1 mice pre-
vented hippocampal synapse loss in 4-month-old APP/
PS1 mice [8], supporting the key role played by the C3
complement component in synapse loss in AD at early
stages of the disease.
A study has reported that exposure to Aβ activates astro-
glial NFκB, resulting in the release of C3 by astrocytes. This
in turn leads to reduced synaptic density and altered den-
dritic morphology [14]. C3 cleavage products including C3a
and C3b have been shown to mediate Aβ phagocytosis under
pathological conditions [43, 90].
In AD, as showed in development and adulthood, CR3 is
exclusively expressed by microglia. Deletion of CR3 has been
shown to be protective both in vitro and in vivo [8, 91]. While
injection of Aβ oligomers in WT mice resulted in synapse
loss, Aβ oligomers failed to induce synapse loss in of CR3
KO mice [8], supporting the role played by the complement
in synapse removal during AD.
Additionally, a new phagocytic-independent role of
CR3 has been attributed to this receptor in AD models.
APP AD mice with deleted CR3 expression presented less
Aβ load and reduced interstitial soluble Aβ when compared
with APP mice expressing normal CR3 levels [91]. Alto-
gether, CR3 mediates phagocytosis-dependent Aβ plaque
and synapse removal and also phagocytosis-independent
interstitial soluble Aβ elimination. Further studies in AD
Table 2: Cellular localization of complement components in adulthood and aging.
Cell type Localization Experimental model Method Ref.
C1q
Neuron Synaptic puncta
In vivo: C57BL/6 mice
Human tissue
IHC [32]
Microglia Cellular
In vitro: mice primary culture
In vivo: C57BL/6, C1qa deletion mice
qRT-PCR, IF, IHC, WB [30–33]
Astrocyte Exosomes Human plasma Immunoassay [34]
C3
Microglia Cellular In vitro: mice primary cultures qRT-PCR, IF, ICC, WB [30, 31, 35]
Astrocyte
Cellular In vitro: mice primary cultures qPCR, IF, WB, RNA-seq [30, 35, 36]
Exosomes Human plasma Immunoassay [34]
CR3
Microglia — In vitro: mice primary culture qRT-PCR, IF [31]
C3aR
Neuron Cellular
In vitro: cultured neural stem cells, rat
In vivo: WT mice and rat
In situ hybridization, IF [41, 42]
Microglia Cellular
In vivo: WT mice
Human tissue
In situ hybridization, IF, IMC [37–39]
Astrocyte Cellular In vitro: CB193 cell line, human astrocyte cultures IF, RT-PCR, IP [39, 40]
qRT-PCR: semiquantitative PCR; ICC: immunocytochemistry; IHC: immunohistochemistry; WB: Western blot; IF: immunofluorescence; FACS: fluorescence-
activated cell sorting; IP: immunoprecipitation.
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models are required to further expand the key role played by
CR3 in AD progression.
Finally, not only CR3 but also microglial C3aR receptors
might be involved in synaptic loss in AD [14, 37]. Aβ induces
astrocytic release of C3 via NFκB activation, which in turn
interacts with microglial C3aR to mediate pathology in AD
[14, 37]. C3aR is also expressed by neurons in AD [14].
Hence, in summary, the presence of oligomeric/fibrillar
Aβ at the synaptic area increases the levels of C1q and binds
to it. As a result of which, the levels of C3 increase and its
cleavage product iC3b binds to microglial CR3, which in turn
results in synapse removal (Figure 1(c)).
6. CR1 and AD
CR1 is a transmembrane glycoprotein that can be found in
the plasma membrane of erythrocyte and monocyte/macro-
phage among other cells and is involved in the phagocytosis
of complement-opsonized pathogens [92].
In the periphery, CR1 is mainly expressed by erythrocytes
and is involved in the clearance of complement-opsonized
pathogens. It has been reported that peripheral Aβ is opson-
ized by the complement and captured by erythrocyte and
monocyte/macrophage CR1 [21, 93]. In AD patients, capture
of Aβ by erythrocytes is reduced [21, 93] and Aβ immuno-
therapy improves this clearance mechanism in vitro and in
living primates [21].
Several laboratories have studied the cellular localization
of CR1 within the brain. In 1996, Gasque and Morgan [38]
reported that CR1 is expressed by primary human astrocytes
and T193 astrocytes in vitro. Those results were later con-
firmed using immunohistochemistry in human tissue sec-
tions from normal and multiple sclerosis (MS) brains [38].
However, in 1999, Singhrao et al. were unable to detect
CR1 in neurons, astrocytes, or microglia [94].
In 2009, a GWAS study identified single-nucleotide poly-
morphisms (SNP) in CR1 that were associated with late onset
AD and therefore as a risk factor for the disease [77]. Further
work confirmed this association [95–99], and the study of its
cellular localization in the CNS intensified.
While Allen et al. and Karch et al. [100, 101] reported
CR1 mRNA expression on cortical homogenates of AD
brains, Holton et al. [102] found CR1 to be associated specif-
ically with the frontal cortex white matter and cerebellum in
AD samples. At cellular level, Hazrati et al. [103] showed
CR1 immunoreactivity in neurons, choroid plexus, and
blood cells of human origin, whereas CR1 localization in
human microglia was not evident.
Based on the genetic association, expression, and func-
tion, in 2016, Fonseca et al. [104] analyzed the role of CR1
in AD. They showed the specificity of two monoclonal anti-
CR1 antibodies for astrocytes both in human tissue samples
and in human brain-derived astrocyte cultures. Nonspecific
immunoreactivity in neurons or microglia was detected.
Table 3: Cellular localization of complement components in Alzheimer’s disease.
Cell type Localization Experimental model Method Ref.
C1q
Neuron
Cellular Human tissue IHC, in situ hybridization [88]
Synaptic puncta In vivo: J20 mice IF [8]
Microglia — In vivo: J20 mice IF [8]
Astrocyte
Cellular
In vitro: human primary culture
In vivo: 5xFAD mice
ELISA, IF [84, 89]
Exosomes Human plasma samples Immunoassay [34]
C3
Neuron Synaptic puncta In vivo: J20 mice IF [8]
Microglia —
In vitro: mice primary culture
In vivo: APPswe/PS1dE9 mice
qPCR, IP, in situ hybridization [35, 37]
Astrocyte
—
In vitro: mice primary culture
In vivo: APP/TTA, APPswe/PS1dE9 mice
qPCR, in situ hybridization, IC [30, 37]
Cellular In vivo: APP mice IF [124]
— Human tissue qPCR, in situ hybridization [14]
Exosomes Human plasma Immunoassay [34]
CR3
Microglia Cellular
In vitro: mice primary culture, BV2 cell line
In vivo: J20 mice
IF, WB [8, 91]
C3aR
Neuron —
In vitro: mice primary culture
In vivo: APP/TTA mice
IF [118]
Microglia —
In vitro: mice primary culture
In vivo: APPswe/PS1dE9 mice
qPCR, in situ hybridization [37]
qRT-PCR: semiquantitative PCR; ICC: immunocytochemistry; IHC: immunohistochemistry; WB: Western blot; IF: immunofluorescence; FACS: fluorescence-
activated cell sorting; IP: immunoprecipitation.
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The authors determined that the use of different antibodies
with different reactivities or levels of detection could explain
differences among different laboratories [104]. They also
reported that neither CR1 distribution in the brain nor its
binding activity correlated with AD-related CR1 polymor-
phisms and diagnostics. They concluded that further func-
tional studies on peripheral CR1 on red cells might bring
light on how this receptor contributes to AD.
A recent study by Johansson et al. [105] investigated the
peripheral interaction of CR1 with Aβ in AD and was also
unable to detect CR1 expression in the brain. By contrast
and in line with previous results by their lab [93] as well as
those by Fonseca et al. [104], they showed that CR1 in eryth-
rocytes was significantly reduced in AD. CR1-mediated
erythrocyte capture of circulating Aβ was also significantly
reduced. Moreover, the SNP of CR1 that increases AD risk
was associated with decreased CR1 in erythrocytes, while
the SNP of CR1 that decreases AD risk was associated with
increased CR1 in erythrocytes.
In summary, while CR1 localization in the peripheral
nervous system has been strongly supported, the CR1 expres-
sion in the brain is still open to debate. If it is indeed
expressed in the brain, CR1 might play a role in synapse
pruning, as it is a receptor for opsonized complexes.
7. Beneficial versus Detrimental Role of
Complement in AD
Reported data indicate that the complement system might
have a dual role in AD. Some authors argue that the comple-
ment is neuroprotective. As a matter of fact, some comple-
ment factors like C3 have been reported to decrease the
neuropathology in hAPP mice [43]. C3 and CR3 are involved
in fibrillar Aβ phagocytosis in vitro [106]. Also, a study
carried out using APP/C3−/− mice suggested that C3 may
have a beneficial role in plaque clearance and neuronal health
in AD. It should be noted that such study was done using 12-
and 17-month-old mice [90]. C1q has also been proven to
have a neuroprotective role against Aβ toxicity both in vitro
and in mice [107].
However, numerous researchers claim that the comple-
ment plays a detrimental role in AD. An APP C1q KOmouse
model showed less glial activation and decreased synapse loss
and neuronal degeneration [108]. Also, treatment with a
C3aR antagonist that blocked the C3 signal in APP mice res-
cued cognitive impairment [14]. In another study, oligomeric
Aβ failed to induce synaptic loss in C1qa KO mice, C3 KO
mice, and in mice with microglia-lacking CR3 [8]. Also, inhi-
biting microglial CR3 reduced Aβ pathology [37]. Recent
publications demonstrated that lifelong C3 deficiency par-
tially protects against age- and Aβ-associated hippocampal
synapse loss in mice [109, 110]. Although C3 deficiency
resulted in less Aβ clearance and, therefore, more plaques,
the mice had more synapses and better cognitive function,
suggesting that the immune response to Aβ was the cause
of neurodegeneration. Moreover, microglia-lacking CR3 is
more efficient in degrading Aβ [91]. It has also been shown
that activation of the complement system worsens tau
pathology in AD models (reviewed in [111]).
All these contradictory results may be due in part to
the variety of experimental models used and the different
ages at which mice were studied. Also, different brain
regions were analyzed. Studies that found C3 to be benefi-
cial for Aβ clearance and neuronal death were carried out
using APP [90] and hAPP [43] mice older than 10 months
with well-established Aβ plaque pathology. However, some
of the studies that found C1q, C3, and CR3 to be detri-
mental for Aβ clearance and synapse health used J20 [8]
and APP [91] mice at preplaque stages.
Acute versus chronic complement activation may also be
a key for understanding its dual role in AD pathology. Lian
et al. [14] showed that short-term treatment of microglia
with C3 or C3a promoted phagocytosis, whereas longer treat-
ment diminished it.
As in AD, complement inhibition is protective in other
neurodegenerative diseases. Increased expression of C1q by
microglia [112] and in synapses has been reported in murine
models of glaucoma, and its inhibition prevented synapse
degeneration [113]. Moreover, C1qa was upregulated in
microglia and neurons during West Nile virus infection and
lack of C3 or C3aR in KO mice protected against virus-
induced synaptic loss [114]. It has also been reported that
complement contributes to cell and myelin damage in MS,
with an upregulation of C1q, C3, and C3-activated products
in patients’ hippocampi [115] and plaques [116].
Finally, neuroglia express inhibitory protective molecules
to prevent uncontrolled complement-mediated damage, such
as CD59, complement factor H (CFH), and complement
receptor-related protein-y (Crry), which mainly interfere
with C3 [19, 117]. Modification of the expression of these
molecules in the context of AD needs additional investiga-
tion. Whether the complement plays a beneficial or a detri-
mental role in AD needs further clarification.
8. Other Pathways Involved in Synapse Removal
Besides complement-mediated synapse removal, other path-
ways have been described to be involved in glia-neuron inter-
action that might also result in synapse elimination (reviewed
in [118]). Astrocytes have been described to be implicated in
activity-dependent synapse elimination via multiple EGF-
like domains 10 (MEGF10) and Mer tyrosine kinase
(MERTK) pathways [119]. Recently, phagocytic capacity of
reactive astrocytes via ABCA1 and its pathway molecules,
MEGF10 and GLUP1, after transient brain ischemia has also
been reported [120]. Also, the phagocytic clearance capacity
of plaque-associated reactive astrocytes of presynaptic
dystrophies in an APP/PS1 AD mouse model has been
demonstrated [121].
Microglial Cx3cr1 receptor might also regulate synaptic
spine maintenance as reported by Paolicelli et al. [122].
Cx3cr1 KO mice showed increased levels of PSD-95 and
synaptic puncta when compared to WT mice, suggesting a
deficit in synaptic pruning. Also, only spontaneous vesicle
release was observed. This was an indication for immature
connectivity in the KO animals [122].
Additionally, a recent report [123] indicates that previ-
ously described phagocytosis of synapses by microglia might
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be only partial and involves specifically presynaptic termi-
nals. The role of complement cascade in this selective phago-
cytosis and the requirement of glial cells need to be
investigated. Additional research including knowledge about
the involved signaling pathways as well as the effect of genet-
ics, aging, disease, and brain region among others is needed
to understand glia-mediated synaptic elimination.
9. Conclusions
Understanding the biology behind synapse loss in AD is
crucial to the discovery of new and more efficient therapeu-
tic targets, ultimately aiming to stop or reverse early stages
of disease progression. In vitro studies showed that both
intracellular [53–56] and extracellular [57, 58] Aβ are associ-
ated to synapse pathology. As a matter of fact, Aβ accumula-
tion itself is capable of inducing synapse loss in isolated
neurons. However, in vivo studies have demonstrated the
important contribution of both microglia and astrocytes to
AD-related synapse loss. Recent studies point towards a key
role played by the complement pathway, specifically by C1q
and/or C3 initiator proteins, as the mechanism by which glial
cells modulate synapse pruning. Such mechanism may take
place not only during development but also during AD-
related neurodegeneration. Therefore, different effectors
might be contributing to AD-associated synapse loss via
different mechanisms.
The contribution of neurons and glial cells to synapse
removal, both in health and during neurodegeneration,
remains not well understood and needs further investigation.
A number of studies suggest that there might be additional
factors involved in the regulation of synaptic pruning. Thus,
new knowledge on cellular and molecular contributors will
shed light to the understanding of this complex machinery.
Additional Points
Highlights. Amyloid-induced synapse loss in AD may occur
via both neuron-autonomous mechanisms and nonautono-
mous mechanisms involving glial cells. Glial cells contribute
chiefly to synapse pruning via the complement pathway.
The complement pathway plays a key role in glia-mediated
synapse pruning. Glial contribution as a source of comple-
ment components differs during development, adulthood,
normal aging, and Alzheimer’s disease.
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